Myeloma

Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said.

Aphexda was well tolerated and helped the majority of patients collect enough cells to go to transplant, study results showed.

Blenrep did not meet its progression-free survival endpoint in a phase 3 clinical trial for patients with relapsed or refractory multiple myeloma.

Stem cell transplants may cause dysgeusia — a disorder that alters a person’s taste —in some patients with multiple myeloma, which is a type of blood cancer. This disorder may have a domino effect on quality of life, although levels may return to normal a few months after the procedure, an expert said.

The FDA’s approval of Tecvayli was based on findings showing that 61.8% of patients with pretreated, relapsed/refractory myeloma responded to the drug.

In 2018, 18 trekkers completed an awe-inspiring hike of the Himalayan highlands to the doorstep of the world’s tallest mountain, Mount Everest, to raise awareness and funding for multiple myeloma, a type of blood cancer. Three of the climbers discuss a bond that hasn’t broken.

The FDA’s Oncologic Drugs Advisory Committee voted against the continued approval of Pepaxto for pretreated relapsed/refractory myeloma, based on survival data from a clinical trial.

Delivering Sarclisa via an under-the-skin injection may improve the quality of life of patients with pretreated relapsed, refractory multiple myeloma, according to recent research.

Firefighters and recovery workers exposed to the aftermath of 9/11 in New York City had a higher occurrence of MGUS, a condition which may progress to myeloma, according to recent research.

Long-term follow-up shows that treatment with Empliciti plus pomalidomide and dexamethasone continues to significantly increase survival rates in patients with relapsed or refractory multiple myeloma, a persistent cancer affecting white blood cells that may be resistant to treatment.

Lisa’s excellent fund of knowledge, experience in oncology, outstanding judgment and interest in learning all make her a truly outstanding clinician.

The use of five or more medicines — as well as some drugs that could be deemed inappropriate — may put older patients with cancer at a higher risk for complications, such as weakness.

Data from a clinical trial demonstrate a “clear clinical benefit” of using a CAR-T cell therapy in patients with multiple myeloma, according to the drugs manufacturer.

Findings from previous studies have shown that patients with blood cancers have been less likely to produce antibodies that protect them against COVID-19 after vaccination, but new research indicates that the booster shot may help.

The myeloma treatment group of the COVALENT-101 clinical trial recently started, analyzing the new drug BMF-219 in patients with relapsed or refractory disease.

She has helped me so much with my medications, and she always lifts me up when I need it most.

One patient turned her diagnosis of multiple myeloma into a way to educate others as an advocate.

The best advocate for a patient with cancer is someone who knows exactly what they're going through, noted a multiple myeloma survivor.

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

The hope, according to an expert, is that this trial will expand CAR-T cell therapy access to more patients with multiple myeloma.

The combination of Sarclisa, Kyprolis and dexamethasone improved progression-free survival in patients with pretreated, relapsed myeloma, and has potential to become a new standard of care, an expert said.

They work as a team always. In this way, they are always up-to-date on each and every patient’s condition and needs.

As anyone who has sat at the bedside of a terminally ill patient knows, those who hold out a hand — literally or figuratively — to help a patient and their loved ones is a hero to them.

In recent years, BCMA-targeted therapies have changed the landscape of relapsed/refractory myeloma treatment, filling a previously unmet need.

The results, according to the study authors, may highlight a bigger issue related to structural racism in health care.

Watch Kristie L. Kahl, with Sham Mailankody, MBBS; Cesar Rodriguez, MD; and Lynn Steele, discuss new therapies on the horizon, during the CURE Educated Patient Multiple Myeloma Summit.

Here are some key takeaways from the CURE® Educated Patient® Multiple Myeloma Summit.

Watch Dr. Cesar Rodriguez, of the Multiple Myeloma Program at the Ichan School of Medicine at Mount Sinai, discuss upcoming FDA approvals in the space, during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Sham Mailankody, from Memorial Sloan Kettering Cancer Center, discuss CAR and BiTE therapy, during the CURE Educated Patient Multiple Myeloma Summit.